Acadia Pharmaceuticals vs ANI Pharmaceuticals
ACAD and ANIP side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ACAD and ANIP compare
Acadia Pharmaceuticals is the larger company, worth 2.0 times as much as ANI Pharmaceuticals ($3.2B against $1.6B).
On earnings, Acadia Pharmaceuticals is cheaper: it trades at 8.9× trailing earnings, against 13.5× for ANI Pharmaceuticals.
ANI Pharmaceuticals grew revenue faster over the last twelve months (25.9% versus 14.8% for Acadia Pharmaceuticals).
Acadia Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 30.1% compared with 11.2% at ANI Pharmaceuticals.
Acadia Pharmaceuticals scores higher on the StockData Score (17 against 15 for ANI Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ACAD | ANIP |
|---|---|---|
| Size and price | ||
| Market cap | $3.2B | $1.6B |
| Share price | $18.75 | $71.44 |
| Change, 1 year | −22.3% | −18.1% |
| Change, 5 years | −2.1% | 64.1% |
| Beta (5Y) | 0.78 | 0.61 |
| Employees | 798 | 970 |
| StockData Score | ||
| Total score | 17 (better) | 15 |
| Valuation score | 5 | 5 |
| Growth score | 2 | 2 |
| Performance score | 4 | 4 |
| Health score | 6 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 8.9× (better) | 13.5× |
| P/S | 2.7× | 1.6× (better) |
| P/B | 2.3× (better) | 2.6× |
| EV/EBITDA | 18.4× | 6.1× (better) |
| P/FCF | 39.4× | 8.0× (better) |
| FCF yield | 2.5% | 12.5% (better) |
| Fair value | $31.63 | $153.69 |
| Margin of safety | 40.7% | 53.5% (better) |
| Growth | ||
| Revenue growth (TTM) | 14.8% | 25.9% (better) |
| Revenue growth, 5Y average | 19.4% | 33.5% (better) |
| Net income growth (TTM) | 38.7% | 188% (better) |
| EPS growth (TTM) | 35.5% | 225% (better) |
| Profitability | ||
| Gross margin | 90.5% (better) | 61.1% |
| Operating margin | 10.2% | 16.0% (better) |
| Net margin | 30.1% (better) | 11.2% |
| FCF margin | 6.8% | 19.7% (better) |
| Return on equity | 31.4% (better) | 20.4% |
| Return on invested capital | 50.8% (better) | 23.0% |
| Financial health | ||
| Debt / equity | 0.00 | 0.47 (better) |
| Net debt / EBITDA | – | −0.49 |
| Interest coverage | – | 5.4× |
| Current ratio | 3.82 (better) | 2.75 |
| Altman Z-score | 4.94 (better) | 2.57 |
| Piotroski F-score | 6 | 7 (better) |
| Dividends and buybacks | ||
| Payout ratio | – | 0.00% |
| Buyback yield | −1.5% | 1.2% (better) |
| Shareholder yield | −1.5% | 1.2% (better) |
| Ownership | ||
| Held by institutions | 97.9% | 100% |
| Held by insiders | 27.8% | 12.3% |
| Insider net buying, 12 months | −$2.5M (better) | −$13.6M |
| Short interest, % of float | 6.7% | 17.8% |
Go deeper
- ACAD stock overview
- ACAD income statement
- ACAD valuation and score
- ANIP stock overview
- ANIP income statement
- ANIP valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.